Kiadis Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Kiadis Pharma's estimated annual revenue is currently $10.5M per year.
- Kiadis Pharma's estimated revenue per employee is $155,000
- Kiadis Pharma has 68 Employees.
- Kiadis Pharma grew their employee count by -36% last year.
Kiadis Pharma Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Kiadis Pharma?
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Kiadis Pharma is committed to developing innovative and potentially life'saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.keywords:N/A
Number of Employees
Employee Growth %
Kiadis Pharma News
Kiadis Pharma; Cytovia Therapeutics; Nkarta, Inc; Fate Therapeutics; EMERcell; Glycostem; Phio Pharmaceuticals, Innate Pharma, Inc...
... Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and Medexus Pharma, Inc. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics...
Bluebird Bio; Novartis; Kiadis Pharma; Acceleron Pharma. Alpha Thalassemia Market Breakdown by Type: Iron Chelating Drugs; Gene Therapy.
Amsterdam, The Netherlands - Kiadis Pharma N.V. ('Kiadis Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders ('AGM') will be held at 15:00 CEST on 28 June 2021. Pursuant to tempor ...
Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of shareholders ("AGM”) will be held at 15:00 CEST on 28 June 2021. ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|